Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population

Pancreas

Volumn 41, Issue 3, 2012, Pages 461-466

  Beaumont, Jennifer L ^a   Cella, David ^a   Phan, Alexandria T ^b   Choi, Seung ^a   Liu, Zhimei ^c   Yao, James C ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

carcinoid; carcinoid syndrome; diarrhea; flushing; health related quality of life; neuroendocrine tumor

Indexed keywords

ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVOR; CARCINOID SYNDROME; CONTROLLED STUDY; FEMALE; FLUSHING; HEALTH SURVEY; HUMAN; INTESTINE MOTILITY; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROENDOCRINE TUMOR; PATIENT REPORTED OUTCOME MEASUREMENT INFORMATION SYSTEM 29; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; UNITED STATES;

CASE-CONTROL STUDIES; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; DIARRHEA; FEMALE; FLUSHING; HEALTH SURVEYS; HUMANS; INTERNET; LINEAR MODELS; MALE; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMORS; QUALITY OF LIFE; QUESTIONNAIRES; UNITED STATES;

EID: 84859060426     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182328045     Document Type: Article

References (25)

1. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25(3):458-511. (Pubitemid 38780668)
2. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063- 3072.
3. Janson ET. Treatment of neuroendocrine tumors with somatostatin analogs. Pituitary. 2006;9(3):249-256. (Pubitemid 44742287)
4. Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8(7):685-690. (Pubitemid 27372168)
5. Frojd C, Larsson G, Lampic C, et al. Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health Qual Life Outcomes. 2007;5:18.
6. Haugland T, Vatn MH, Veenstra M, et al. Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population. Qual Life Res. 2009;18(6):719-726.
7. Pezzilli R, Campana D, Morselli-Labate AM, et al. Patient-reported outcomes insubjects with neuroendocrine tumors of the pancreas. World J Gastroenterol. 2009;15(40):5067-5073.
8. Frojd C, Lampic C, Larsson G, et al. Is satisfaction with doctors' care related to health-related quality of life, anxiety and depression among patients with carcinoid tumours? A longitudinal report. Scand J Caring Sci. 2009;23(1):107-116.
9. Larsson G, Haglund K, Von Essen L. Distress, quality of life and strategies to 'keep a good mood' in patients with carcinoid tumours: patient and staff perceptions. Eur J Cancer Care (Engl). 2003;12(1):46-57. (Pubitemid 37255606)
10. Larsson G, Janson ET. Anemia in patients with midgut carcinoid, treated with alpha interferon: effects by erythropoietin treatment on the perceived quality of life. Eur J Cancer Care (Engl). 2008;17(2):200-204.
11. Larsson G, LVONE, Sjoden PO.Are importance-satisfaction discrepancies with regard to ratings of specific health-related quality-of-life aspects valid indicators of disease- and treatment-related distress among patients with endocrine gastrointestinal tumours? Eur J Cancer Care (Engl). 2007;16(6):493-499.
12. Larsson G, Sjoden PO, Oberg K, et al. Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours. Acta Oncol. 2001;40(7):825-831. (Pubitemid 34081662)
13. Larsson G, Sjoden PO, Oberg K, et al. Importance-satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumours. Ann Oncol. 1999;10(11):1321- 1327.
14. Larsson G, von Essen L, Sjoden PO. Quality of life in patients with endocrine tumors of the gastrointestinal tract: patient and staff perceptions. Cancer Nurs. 1998;21(6):411-420. (Pubitemid 28545851)
15. Larsson G, von Essen L, Sjoden PO. Health-related quality of life in patients with endocrine tumours of the gastrointestinal tract. Acta Oncol. 1999;38(4):481-490. (Pubitemid 29305724)
16. Von Essen L, Larsson G, Oberg K, et al. 'Satisfaction with care': associations with health-related quality of life and psychosocial function among Swedish patients with endocrine gastrointestinal tumours. Eur J Cancer Care (Engl). 2002;11(2):91-99.
17. Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Clin Oncol. 2004;22(13):2724-2729. (Pubitemid 41103761)
18. Ware JE Jr, Snow KK, Kosinski M, et al. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Centre; 1993.
19. Choi S, Cella D. Comparison of PROMIS Health Profile Short Forms & CAT. Paper presented at AcademyHealth Annual Research Meeting 2009, Chicago, IL.
20. Eton DT, Cella D, Yost KJ, et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol. 2004;57(9):898-910. (Pubitemid 39422527)
21. Cohen J. Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, Publishers; 1988.
22. Davies AH, Larsson G, Ardill J, et al. Development of adisease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours. Eur J Cancer. 2006;42(4):477-484. (Pubitemid 43227926)
23. Vinik E, Carlton CA, Silva MP, et al. Development of the Norfolk quality of life tool for assessing patients with neuroendocrine tumors. Pancreas. 2009;38(3):e87-e95.
24. Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3(8):761-771. (Pubitemid 41116728)
25. Wymenga AN, Eriksson B, Salmela PI, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol. 1999;17(4):1111.